A Phase 1 interventional study of BMS-986278 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986278 · Drug: Placebo
Drug: BMS-986278
Drug: BMS-986278 · Drug: Placebo
Drug: Placebo
Drug: Placebo · Drug: Moxifloxacin
Drug: BMS-986278
Drug: BMS-986278 · Drug: Placebo
Drug: Placebo
Drug: Placebo · Drug: Moxifloxacin
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Number of participants with non-serious Adverse Events (AEs)
Part A
Time frame: Until 28 days post last treatment dose
Number of participants with Serious AEs (SAEs)
Part A
Time frame: Until 28 days post last treatment dose
Number of participants with AEs leading to study intervention discontinuation
Part A
Time frame: Until 28 days post last treatment dose
Number of participants with vital sign abnormalities
Part A
Time frame: Up to Day 18
Number of participants with clinical laboratory assessment abnormalities
Part A
Time frame: Up to Day 18
Number of participants with 12-lead electrocardiogram (ECG) abnormalities
Part A
Time frame: Up to Day 18
Number of participants with physical examination abnormalities
Part A
Time frame: Up to Day 18
Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Placebo-corrected change from baseline QTcF (ΔΔQTcF)
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Maximum observed plasma concentration (Cmax)
Part A and Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Time of maximum observed plasma concentration (Tmax)
Part A and Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Area under the plasma concentration-time curve from time zero to the end of dosing interval AUC(TAU)
Part A and Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Terminal half-life (T-HALF)
Part A
Time frame: Up to Day 18
Apparent total body clearance (CLT/F)
Part A
Time frame: Up to Day 18
Change from baseline heart rate (HR) (∆HR)
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Change from baseline PR interval (∆PR)
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Change from baseline QRS interval (∆QRS)
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Placebo-corrected change from baseline HR (ΔΔHR)
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Placebo-corrected Change from baseline PR interval (ΔΔPR)
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Placebo-corrected change from baseline QRS interval (ΔΔQRS)
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Number of participants with categorical outliers for QTcF
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Number of participants with categorical outliers for HR
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Number of participants with categorical outliers for PR interval
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Number of participants with categorical outliers for QRS interval
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Number of participants with treatment-emergent changes of ECG morphology
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
ΔQTcF for moxifloxacin
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
ΔΔQTcF for moxifloxacin
Part B
Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Number of participants with non-serious AEs
Part B
Time frame: Until 28 days post last treatment dose
Number of participants with SAEs
Part B
Time frame: Until 28 days post last treatment dose
Number of participants with AEs leading to study intervention discontinuation
Part B
Time frame: Until 28 days post last treatment dose
Number of participants with vital sign abnormalities
Part B
Time frame: Up to Day 18 of Period 4 (Each period is 17 days)
Number of participants with clinical laboratory assessment abnormalities
Part B
Time frame: Up to Day 17 of Period 4 (Each period is 17 days)
Number of participants with 12-lead ECG abnormalitie
Part B
Time frame: Up to Day 17 of Period 4 (Each period is 17 days)
Number of participants with physical examination abnormalities
Part B
Time frame: Up to Day 18 of Period 4 (Each period is 17 days)
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Feb 2025 to primary completion in Sep 2025, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Admilparant · Moxifloxacin